This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ORPH Orphazyme A/S (ORPH) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Orphazyme A/S Stock (NASDAQ:ORPH) 30 days 90 days 365 days Advanced Chart Get Orphazyme A/S alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.57▼$2.2152-Week Range N/AVolume941,400 shsAverage Volume1.37 million shsMarket Capitalization$30.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOrphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.Read More… Receive ORPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orphazyme A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address ORPH Stock News HeadlinesHow Four Sigmatic Made Mushrooms A Multi-Billion Dollar CategoryNovember 11, 2024 | forbes.comWeight loss care is leading IPO-hopeful Omada Health's latest growth surge as Ozempic boom continuesOctober 30, 2024 | businessinsider.comWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.June 25, 2025 | Crypto Swap Profits (Ad)Incyte’s Strong Financial Performance and Promising Pipeline Lead to Buy RatingOctober 30, 2024 | markets.businessinsider.comOzempic could help reduce Alzheimer’s risk for some, study suggests: ‘Shifting the paradigm’October 26, 2024 | msn.comAquestive Therapeutics’ Favorable OAS Study Boosts Anaphylm’s Prospects with Raised Price Target and Buy RatingOctober 25, 2024 | markets.businessinsider.comNovo’s Ozempic Linked to Reduced Alzheimer’s DiagnosesOctober 24, 2024 | msn.comHow Europe's Biggest Buyout Deal Descended Into a Bruising BrawlOctober 24, 2024 | bloomberg.comSee More Headlines ORPH Stock Analysis - Frequently Asked Questions When did Orphazyme A/S IPO? Orphazyme A/S (ORPH) raised $100 million in an initial public offering on Tuesday, September 29th 2020. The company issued 7,600,000 shares at $13.13 per share. BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO and Danske Markets was co-manager. What other stocks do shareholders of Orphazyme A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Orphazyme A/S investors own include AMC Entertainment (AMC), Digital World Acquisition (DWAC), NIO (NIO), Biora Therapeutics (BIOR), SNDL (SNDL), Tesla (TSLA) and Brigham Minerals (MNRL). Company Calendar Today6/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ORPH CIK1764791 Webwww.orphazyme.com Phone45-2898-9055FaxN/AEmployees141Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.14 Current Ratio1.80 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.74 per share Price / BookN/AMiscellaneous Outstanding Shares35,312,000Free FloatN/AMarket Cap$30.72 million OptionableNot Optionable Beta1.68 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:ORPH) was last updated on 6/25/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orphazyme A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Orphazyme A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.